Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received notification from the US Patent and Trademark Office (USPTO) that the patent application 'Treatment of Bone Marrow Pathologies with Polysulfated Polysaccharides' (US application number 16/636,545) has been examined and received a Notice of Allowance in the US.
The Notice of Allowance is only handed out after an examiner determines that a patent application satisfies the requirements for patentability.
A summary of the first claim of the accepted patent (16/636,545) refers to a method for improving knee function in a human having bone marrow edema lesions as assessed by magnetic resonance imaging (MRI) and osteoarthritis in a knee, the method including the treatment of the knee with administering an amount of pentosan polysulfate.
Building IP portfolio
Paradigm managing director Paul Rennie referred to the notification as an “excellent outcome for Paradigm as we continue to build on the strength of our IP portfolio across all our indications”.
Rennie said, “We are focused on continuing to add additional layers of protection as data becomes available from our preclinical and clinical programs.
"The Paradigm team continues to further build patent protection around iPPS, a potential blockbuster therapeutic for osteoarthritis. The company looks forward to further updating shareholders on additions to our IP portfolio.”
About Paradigm
PAR is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing and delivering pharmaceutical therapies.
Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).